Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Open-label Phase 2 Study to Evaluate the Efficacy and Safety of Tislelizumab in Combination With Fruquintinib in Patients With Selected Solid Tumors

NCT04716634 is registered in ClinicalTrials.gov with BeiGene as lead sponsor.

NCT NCT04716634
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04716634 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Open-label Phase 2 Study to Evaluate the Efficacy and Safety of Tislelizumab in Combination With Fruquintinib in Patients With Selected Solid Tumors
Lead sponsor
BeiGene
Phase
Phase 2
Overall status
Completed
Start date
April 19, 2021
Completion date
February 22, 2024
Enrollment
84 (actual)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid tumors